Effects of the ketogenic diet on cognition: a systematic review.


Journal

Nutritional neuroscience
ISSN: 1476-8305
Titre abrégé: Nutr Neurosci
Pays: England
ID NLM: 100892202

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 3 11 2023
pubmed: 11 11 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

Ketogenic diet (KD) therapy has been used as a dietary intervention in drug-resistant epilepsy for several years. Research currently suggests that KD therapy may carry neuroprotective and cognition enhancing effects for individuals with non-epileptic conditions as well as for healthy individuals. Therefore, KD may have potential as a non-invasive, nutritional treatment approach for difficult to manage conditions such as neurodegenerative illnesses or mood disorders. The aim of this review is to summarize the available evidence on ketogenic interventions and the resulting cognitive outcomes. The paper was based on PRISMA 2020 guidelines. The search was conducted in June 2021 on the following databases: CENTRAL, PubMed, EMBASE, PsycInfo, Web of Science. The search yielded 2014 studies, of which 49 were included. There were 22 animal studies assessing murine models and 27 studies on humans. The primary indications in these studies were epileptic conditions, neurodegenerative disorders, cognitive impairment, and healthy populations. Administration of KD seems to confer cognitive-enhancing effects in areas such as working memory, reference memory and attention. Studies found that KD treatment in animals has the potential to alleviate age-related cognitive decline. Over 80% of the 27 human studies reported a favourable effect of intervention, and none reported a detrimental effect of KD. While these findings suggest that KD may improve the functioning of certain cognitive domains, definitive conclusions were limited by studies with small sample sizes, the absence of controls and randomization, and the lack of objective measures of cognition.

Identifiants

pubmed: 36354157
doi: 10.1080/1028415X.2022.2143609
doi:

Substances chimiques

Ketone Bodies 0

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1258-1278

Auteurs

Arun Chinna-Meyyappan (A)

Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.

Fabiano Alves Gomes (FA)

Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.
Centre for Neuroscience Studies (CNS), Queen's University, Kingston, Canada.

Elena Koning (E)

Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.

Jennifer Fabe (J)

Master Children's Hospital, Hamilton, Canada.

Vitor Breda (V)

Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.
Centre for Neuroscience Studies (CNS), Queen's University, Kingston, Canada.

Elisa Brietzke (E)

Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.
Centre for Neuroscience Studies (CNS), Queen's University, Kingston, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH